Dominion Energy Inc vs Heron Therapeutics Inc — how do they compare? Dominion Energy Inc trades at $61.73 (market cap $54.31B), while Heron Therapeutics Inc trades at $0.4 (market cap $68.01M). The key difference: Dominion Energy Inc is far larger — about 798.6× Heron Therapeutics Inc's market cap, and Dominion Energy Inc pays a 4.32% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dominion Energy Inc for 76 Days and Heron Therapeutics Inc for 35 Days on average.
| D | HRTX | |
|---|---|---|
Market Cap | $54.31B | $68.01M |
Volume | 6,944,775 | 1,891,941 |
Sector | Utilities | Health |
52-Week High | $71.67 | $1.49 |
52-Week Low | $57.08 | $0.27 |
Typical Hold Time | 76 Days | 35 Days |
Enterprise Value | $108.43B | $174.75M |
Dividend Yield | 4.32% | — |
Signals from Pluang's Aura AI — not financial advice
Dominion Energy (D) trades at $61.53, down 0.76% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with revenue growth from $14.5B in 2024 to $16.5B in 2025 and net income margin improving to 18.16%. Analyst consensus is mixed with 36% buy ratings but a $71.56 price target suggesting 16% upside. The pending merger with NextEra Energy dominates recent news coverage, creating both opportunity and regulatory uncertainty.
The stock presents a value opportunity with reasonable valuation multiples (P/E 21.37, P/S 2.96) and consistent profitability, though technical indicators suggest near-term pressure. Key risks include merger approval uncertainty, high debt levels, and interest rate sensitivity. The dividend yield of approximately 4.4% provides income support while investors await merger resolution and continued execution on data center and renewable energy investments.
Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.
The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Based in Richmond, Virginia, Dominion Energy is an integrated energy company with over 30 gigawatts of electric generation capacity and more than 90,000 miles of electric transmission and distribution lines. Dominion owns a liquefied natural gas export facility in Maryland and is constructing a 5.2 GW wind farm off the Virginia Beach coast.
Read more on D →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →